Benefits Outweigh the Risks of AstraZeneca COVID Shot as Review Continues: WHO
GENEVA (Reuters) – A World Health Organization (WHO) vaccine safety panel said on Wednesday that it considers that the benefits […]
» Read moreCredit: CC0 Public Domain Britain insisted Thursday that its plan to ease coronavirus lockdowns in the coming months remained on […] (Reuters) – Three major U.S. drug distributors have requested the government to expand the COVID-19 vaccine supply chain network as […] The World Health Organization (WHO) today listed the COVID-19 vaccine Ad26.COV2.S, developed by Janssen (Johnson & Johnson), for emergency use […] In a new large-scale UK-wide study, led by the University of Glasgow in collaboration with the University of Essex, researchers […] As of February 11, 2021, Moderna had provided the United States with over 41 million doses of the 300 million […] Dogged already by rows with European politicians, AstraZeneca was forced anew to defend its coronavirus vaccine on Friday over concerns […] The World Health Organization said Friday there was no reason to stop using AstraZeneca’s COVID-19 vaccine after several European countries […] Delaying second doses of COVID-19 vaccines should reduce case numbers in the near term. But the longer-term case burden and […] Extensive testing for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a primary mitigation measure in controlling […]
UK denies vaccine shortfall will slow lockdown easing plan
US Drug Distributors Urge Govt to Boost COVID-19 Vaccine Supply Network
Janssen’s vaccine added to list of safe, effective tools against COVID-19
Vaccine hesitancy more likely in young people, women and some ethnic groups
The Delayed Side Effect Of The Moderna Vaccine You Need To Know About
AstraZeneca on back foot again over vaccine safety fears
No reason to stop using AstraZeneca COVID-19 vaccine: WHO
Delaying second doses of COVID-19 vaccines has benefits, but longer-term results rely on robust immunity
Researchers develop assay for qualitative assessment of SARS-CoV-2 neutralizing antibodies
